Literature DB >> 28823823

Immunization of mice with LRP4 induces myasthenia similar to MuSK-associated myasthenia gravis.

Shuuichi Mori1, Norio Motohashi1, Rumi Takashima1, Masahiko Kishi2, Hiroshi Nishimune3, Kazuhiro Shigemoto4.   

Abstract

Since the first report of experimental animal models of myasthenia gravis (MG) with autoantibodies against low-density lipoprotein receptor-related protein 4 (LRP4), there have not been any major reports replicating the pathogenicity of anti-LRP4 antibodies (Abs). Recent clinical studies have cast doubt on the specificity and pathogenicity of anti-LRP4 antibodies for MG, highlighting the need for further research. In this study, we purified antigens corresponding to the extracellular region of human LRP4 stably expressed with chaperones in 293 cells and used these antigens to immunize female A/J mice. Immunization with LRP4 protein caused mice to develop myasthenia having similar electrophysiological and histological features as are observed in MG patients with circulating Abs against muscle-specific kinase (MuSK). Our results clearly demonstrate that active immunization of mice with LRP4 proteins causes myasthenia similar to the MG induced by anti-MuSK Abs. Further experimental and clinical studies are required to prove the pathogenicity of anti-LRP4 Abs in MG patients.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Animal model; Lrp4; MuSK; Myasthenia gravis; Neuromuscular junction

Mesh:

Substances:

Year:  2017        PMID: 28823823     DOI: 10.1016/j.expneurol.2017.08.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

Review 1.  A New Classification System for IgG4 Autoantibodies.

Authors:  Inga Koneczny
Journal:  Front Immunol       Date:  2018-02-12       Impact factor: 7.561

2.  Late-onset Myasthenia Gravis Accompanied by Amyotrophic Lateral Sclerosis with Antibodies against the Acetylcholine Receptor and Low-density Lipoprotein Receptor-related Protein 4.

Authors:  Keiko Ohnari; Kazumasa Okada; Osamu Higuchi; Hidenori Matsuo; Hiroaki Adachi
Journal:  Intern Med       Date:  2018-10-15       Impact factor: 1.271

Review 3.  Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture.

Authors:  Inga Koneczny; Ruth Herbst
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

Review 4.  The Muscle Is Not a Passive Target in Myasthenia Gravis.

Authors:  Jean-Thomas Vilquin; Alexandra Clarissa Bayer; Rozen Le Panse; Sonia Berrih-Aknin
Journal:  Front Neurol       Date:  2019-12-19       Impact factor: 4.003

Review 5.  Impairment Mechanisms and Intervention Approaches for Aged Human Neuromuscular Junctions.

Authors:  Yomna Badawi; Hiroshi Nishimune
Journal:  Front Mol Neurosci       Date:  2020-11-16       Impact factor: 5.639

6.  Characterization of LRP4/Agrin Antibodies From a Patient With Myasthenia Gravis.

Authors:  Zheng Yu; Meiying Zhang; Hongyang Jing; Peng Chen; Rangjuan Cao; Jinxiu Pan; Bin Luo; Yue Yu; Brandy M Quarles; Wencheng Xiong; Michael H Rivner; Lin Mei
Journal:  Neurology       Date:  2021-07-07       Impact factor: 11.800

Review 7.  Animal Models of the Neuromuscular Junction, Vitally Informative for Understanding Function and the Molecular Mechanisms of Congenital Myasthenic Syndromes.

Authors:  Richard G Webster
Journal:  Int J Mol Sci       Date:  2018-04-29       Impact factor: 5.923

8.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.